Nutrinia

Company Overview

Snapshot

Founded in August 2003 by Naim Shehadeh, MD, Nutrinia operated with 1–10 employees. The company raised a total of $44.1 million across four funding rounds from nine investors. BioHealth Partners and TPG Biotech.

Business overview

Nutrinia was a neonatology company focused on developing pharmaceuticals to treat rare gastrointestinal conditions in infants. Its core product in development was an oral insulin formulation designed to enhance gut adaptation and rehabilitation. This powder formulation, intended to be mixed with saline or infant formula, targeted local GI issues without systemic absorption. The company operated within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, serving the United States and Israel markets.

Company Intelligence Q&A

What was Nutrinia's primary focus?

Nutrinia focused on neonatology, developing pharmaceuticals for rare gastrointestinal conditions in infants, with a primary product being an oral insulin formulation.

When was Nutrinia founded?

Nutrinia was founded in August 2003.

What was the status of Nutrinia as of May 2020?

As of May 2020, Nutrinia ceased to operate and is considered Non-Active.

Which investors participated in Nutrinia's D Round in August 2016?

BioHealth Partners and TPG Biotech.